SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is gaining significant momentum as the community rallies around its vision of building a long-term, culture-focused cryptocurrency ecosystem inspired by cannabis heritage. Investors are actively discussing its steady development, upcoming seasonal milestones, and its role as a decentralized alternative to traditional cannabis stocks.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant selling pressure as investors grapple with concerns over the company's heavy capital expenditures on AI infrastructure and shifting narratives around OpenAI's long-term profitability. The community is actively debating the stock's recent trend of failing to participate in broader market relief rallies, with many retail participants expressing frustration over the persistent downward momentum and questioning the effectiveness of leadership's current AI-focused strategy.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing significant volatility as investors weigh the potential long-term demand impact of Google's new TurboQuant memory compression algorithm against the company's strong fundamentals and recent debt tender offer. The community remains deeply divided between those viewing the pullback as a prime buying opportunity for a cyclical leader with a low forward P/E and those bracing for further downside amid broader market uncertainty.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is currently under pressure as investors react to a combination of legal setbacks, including a guilty verdict in a social media harm case, and widespread concerns over the company's aggressive spending on AI infrastructure. While the community is sharply divided between those viewing the decline as a major buying opportunity and others worried about slowing user engagement and potential workforce reductions, the stock remains a central focus for traders navigating a broader sell-off in big-tech growth names.

Pony.ai, Inc. develops artificial intelligence-based robot designed for autonomous driving. The firm's software algorithms and infrastructure enables a vehicle to perceive its surroundings, predict what others will do, and maneuver itself accordingly. The company was founded by Jun Peng and Tian Cheng Lou in November 4, 2016 and is headquartered in Guangzhou, China.

Pony AI Inc. - ADR

Pony AI Inc

Pony AI is currently trending as investors focus on the company's aggressive global expansion strategy, including the recent launch of commercial robotaxi operations in Singapore and partnerships in Europe. The community is actively debating the company's valuation, unit economics, and its competitive positioning against other autonomous vehicle leaders like WeRide and Waymo.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech100 is drawing significant attention as a proxy play for highly anticipated upcoming IPOs, particularly SpaceX, with community members actively debating its valuation relative to its holdings in major unicorns like Anthropic and OpenAI. Investors are closely monitoring the potential for a technical squeeze, weighing the fund's concentrated exposure to private tech leaders against concerns regarding its premium to net asset value and the impact of dilutive share offerings.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as investors grapple with regulatory pressures, including potential bans on prediction markets and ongoing NCAA trademark litigation. The community remains heavily divided, with many traders expressing frustration over persistent downward price action and insider selling, while others treat the volatility as a speculative opportunity.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is capturing community attention through a heavy focus on 'hopecore' social media content and viral campaigns intended to build long-term conviction among holders. Despite ongoing debates about market volatility, supporters remain actively focused on the project's tokenized positivity and collective vision for future growth.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

Market sentiment for SPY is heavily oscillating as investors struggle to parse conflicting news regarding ongoing geopolitical tensions in the Middle East and official rhetoric about potential ceasefires. The community is actively debating the reliability of recent market pumps, with many traders expressing skepticism about the sustainability of these moves amidst reports of potential troop deployments and concerns over energy supply chain stability.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

United States Oil Fund (USO) is experiencing high volatility as the market reacts to conflicting reports regarding potential ceasefire talks between the U.S. and Iran. Investors are closely monitoring geopolitical escalations in the Strait of Hormuz, with community debate centered on whether recent price fluctuations represent a sustainable shift toward de-escalation or merely temporary market manipulation ahead of further conflict.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is the Market Bullish or Bearish on BriaCell Therapeutics Corp?

BriaCell Stock Notches Best Day In 5 Years On Breast Cancer Data — Then Drops 10% After-Hours: What Went Wrong?

Retail chatter on BCTX jumped following the dual news announcements, with Stocktwits sentiment score hitting a one-year high.

Equity

Retail chatter on BCTX jumped following the dual news announcements, with Stocktwits sentiment score hitting a one-year high.


<ul class="summary-bullets"><li>Following four doses of Bria-OTS as a single-agent therapy, the lung metastasis completely disappeared, the company said.</li><li>he 78-year-old patient received a total of 17 treatment cycles, and completed 12 months on the study.</li><li>The company added that the trial has moved into Phase 2A, where Bria-OTS is being tested alongside an immune checkpoint inhibitor.</li></ul>Shares of BriaCell Therapeutics Corp. (BCTX) surged more than 50% on Tuesday after the clinical-stage biotechnology company announced a ‘durable and sustained complete resolution’ of a lung metastasis in a patient with metastatic breast cancer treated with its Bria-OTS immunotherapy.BriaCell said the patient was the first enrolled in its Bria-OTS clinical study and had previously failed multiple lines of treatment. Following four doses of Bria-OTS as a single-agent therapy, the lung metastasis completely disappeared. The response was first seen at two months and has since been confirmed at four, six, and now eleven months.The 78-year-old patient received a total of 17 treatment cycles, completed 12 months on study, and continues to be monitored in survival follow-up. BriaCell noted that the Phase 1 dose-escalation portion of the trial has been completed successfully.The company said the trial has now moved into Phase 2a, where Bria-OTS is being tested alongside an immune checkpoint inhibitor to potentially improve outcomes for patients with advanced breast cancer.“These clinical findings reinforce our confidence in the therapeutic potential and safety of the Bria-OTS platform. Our team remains committed to advancing our novel therapeutic approach with the goal of making a meaningful difference for patients with metastatic breast cancer, particularly those with limited treatment options,” said William V. Williams, BriaCell’s President and CEO.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘neutral’, accompanied by ‘extremely high’ message volumes. <a href="https://stocktwits.com/symbol/BCTX">BCTX</a> was among the top trending tickers on the platform.<img src="https://news.stocktwits-cdn.com/BCTX_jpg_ca990928c1.webp" alt="BCTX.jpg">One bullish user expects the stock to touch $20 today. It is currently at $11.5.<stembedurl>https://stocktwits.com/TommyDel/message/641632538</stembedurl>Another user observed $11 as a key buying zone.<stembedurl>https://stocktwits.com/NoobFriendly/message/641632355</stembedurl>However, the stock has been under heavy selling pressure over the past year, declining more than 87%.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-alb-stock-rising-premarket/cmUXI0pR44w">ALB Stock Garners Retail Attention As Lithium Bulls Return</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

Why Did BCTX Stock Surge 50% Today?

The biotechnology company announced a complete recovery of a lung metastasis in a patient with metastatic breast cancer treated with its Bria-OTS immunotherapy.

Why Did BCTX Stock Surge 50% Today? 

Zacks.com featured highlights include Groupon, BriaCell Therapeutics and InnovAge Holding

Groupon, BriaCell Therapeutics, and InnovAge shine as Zacks' top November picks for powerful earnings acceleration potential.

Top 3 Earnings Acceleration Buys for November 

Groupon, BriaCell Therapeutics and InnovAge stand out with accelerating earnings momentum as November's market optimism approaches. 

All You Need to Know About BRIACELL THERAP (BCTX) Rating Upgrade to Buy

BRIACELL THERAP (BCTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Shares of BriaCell Therapeutics Corp (BCTX) fell over 8% in Thursday's after-hours trading as the Canadian biotech firm priced a public offering of about $13.8 million.&nbsp;Retail investors, however, were focused on positive catalysts from earlier in the day.The West Vancouver, Canada-based company said it is issuing over 3 million shares at $4.50 apiece, more than 25% lower from the last closing price.The offer includes nearly 400,000 units sold through the full exercise of the underwriter's option.Each unit has one common share (or a pre-funded warrant) and one tradeable warrant.&nbsp;BriaCell expects to close the offering on April 28, pending customary closing conditions, and will use the proceeds for working capital, corporate purposes, and advancing its immunotherapy programs.Earlier on Thursday, BriaCell said that a patient in its Phase 1/2a Bria-OTS trial continues to show a complete resolution of lung metastasis, first reported in February 2025, now confirmed at the four-month mark. The news sent the stock up more than 11% in the regular session.The 78-year-old woman with metastatic breast cancer had previously&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bctx-stock-climbs-after-bria-ots-resolves-cancer-metastasis/chPYRuVRAQ">failed</a> several lines of therapy and received the lowest dose level in the study.Upon enrollment in November 2024, the patient had widespread disease, including lung, lymph node, and bone metastases.&nbsp;After receiving Bria-OTS injections every two weeks for six weeks, then every three weeks, her lung metastasis fully resolved, and stable disease has been maintained elsewhere in the body.On Stocktwits, the clinical news took precedence as sentiment for BriaCell turned even more 'extremely bullish' late Thursday amid a 1,266% jump in 24-hour message volume.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/BCTX_sentiment_and_message_volume_as_of_April_24_png_c4da18642c.webp" alt="BCTX sentiment and message volume as of April 24.png" width="1318" height="316"><figcaption>BCTX sentiment and message volume as of April 24. | source: Stocktwits</figcaption></figure>"This is THE most undervalued biotech on NASDAQ, and that will be proven in coming months," posted one user.<stembedurl>https://stocktwits.com/Fvalstounge/message/612629738</stembedurl>"This company should be worth several billion dollars... WOW," wrote another.<stembedurl>https://stocktwits.com/Hannibal_Smith/message/61253769</stembedurl>BriaCell stock, however, has lost over 82% in the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

BriaCell Stock Dips After-Hours On Pricing $13.8M Public Offering, But Retail's Busy Cheering Clinical Milestone

Earlier on Thursday, BriaCell said that a patient in its Phase 1/2a Bria-OTS trial continues to show a complete resolution of lung metastasis.

Nasdaq-listed shares of BriaCell Therapeutics Corp. (BCTX) traded nearly 12% higher on Wednesday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=6008109823653589&amp;symbol=BCTX">announced</a> positive survival data in its Phase 2 study of Bria-IMT plus check point inhibitors (CPI).The Phase 2 study enrolled 54 heavily pre-treated metastatic breast cancer patients.The survival data of patients enrolled in the study with hormone receptor-positive (HR+) metastatic breast cancer exceeds those of patients treated with the prescription medicine Trodelvy, the company said.HR+ metastatic breast cancer patients treated with Bria-IMT plus check point inhibitors had a median overall survival of 17.3 months, exceeding the 14.4 months with Trodelvy in similar heavily pre-treated patients.In patients with triple negative breast cancer, the survival data was similar to patients on Trodelvy but still 70% higher than those of chemotherapy, the company said.CEO William V Williams expressed optimism about the survival benefit data.“Bria-IMT appears to be very well-tolerated,” he said, adding that the company looks forward to confirming the data in its Phase 3 study.Patients with HR+ and TNBC metastatic breast cancer have an overall survival of only a few months and limited therapeutic options.Earlier this month, BriaCell’s majority-owned subsidiary BriaPro Therapeutics Corp announced that it is developing antibodies to B7-H3, a key player in cancer progression, using molecular modeling techniques.On Stocktwits, retail sentiment around BriaCell Therapeutics rose from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume jumped from ‘high’ to ‘extremely high’.<figure class="image"><img style="aspect-ratio:1298/304;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_16_at_12_16_46_PM_png_18e64dcd73.webp" alt="BCTX's Sentiment Meter and Message Volume as of 12:15 p.m. ET on April 16, 2025 | Source: Stocktwits" width="1298" height="304"><figcaption>BCTX's Sentiment Meter and Message Volume as of 12:15 p.m. ET on April 16, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/BCTX">BCTX stock</a> is down by about 52% year-to-date and by about 88% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/icad-stock-soars-merger-announcement-with-radnet/chQPV8HRbOq">iCAD Stock Rockets On Merger Announcement With RadNet: Retail’s Elated</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

BriaCell Stock Rises On Positive Survival Data From Study In Cancer Patients: Retail Gets More Bullish

HR+ metastatic breast cancer patients treated with Bria-IMT plus check point inhibitors had a median overall survival of 17.3 months, exceeding the 14.4 months with Trodelvy in similar heavily pre-treated patients, the company said. 

Shares of BriaCell Therapeutics Corp. rose nearly 2% on Monday afternoon, reversing earlier losses as traders reacted to promising clinical data. Trading volume surged to over 90 times the daily average of about 146,000 shares.BriaCell announced what it called an “unprecedented clinical response,” including the complete resolution of a lung metastasis in a patient with metastatic breast cancer.&nbsp;The patient, a 78-year-old woman who had failed multiple prior treatments, was the first to receive Bria-OTS, a personalized off-the-shelf immunotherapy currently being tested in a Phase 1/2a dose escalation study.At the time of enrollment on Nov. 21, 2024, she had extensive metastases, including multiple bone, lymph node, and lung lesions, according to the company.&nbsp;After receiving four Bria-OTS injections over two weeks, her lung metastasis completely disappeared, while the disease remained stable elsewhere, BriaCell said.Bria-OTS is a next-generation, personalized advancement of BriaCell’s lead candidate, Bria-IMT, which is currently in a pivotal Phase 3 study for metastatic breast cancer.By Monday afternoon, BriaCell was among the top trending tickers on Stocktwits, with the retail messages largely optimistic.“The data on this patient is a true game changer,” wrote one trader, alleging that earlier weakness in the stock was due to short-seller manipulation.<stembedurl>https://stocktwits.com/JJBurch/message/602660557</stembedurl>Traders also noted that H.C. Wainwright more than doubled its price target on BriaCell to $32, implying a nearly 700% upside from current levels.<stembedurl>https://stocktwits.com/Jaymes11/message/602663519</stembedurl>Despite Monday’s gains, BriaCell shares remain down over 90% in the past year. Message volume on Stocktwits has more than tripled in that period, reflecting growing retail interest.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

BriaCell Stock Climbs After ‘Unprecedented’ Immunotherapy Response In Breast Cancer Patient, Retail Exudes Optimism

Bria-OTS is a next-generation, personalized advancement of BriaCell’s lead candidate, Bria-IMT, which is currently in a pivotal Phase 3 study for metastatic breast cancer.

WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters.&nbsp;Our focus is on quality, liquid, growth-oriented, and under-followed companies in sectors actively drawing in capital such as AI, blockchain, biotech and consumer.&nbsp;This real-time news surveillance and targeting combined with our proprietary 5-point analysis, aids in uncovering stocks poised for powerful multi-day or multi-month moves—often long before Wall Street analysts catch on.&nbsp;Here’s what we’re keeping our eyes on:<h3>1. Purple Biotech (NASDAQ: PPBT)</h3>Background: Purple Biotech is a clinical-stage oncology company that aims to redefine cancer treatment through its innovative approaches targeting tumor immune evasion and drug resistance. Its lead product, CM24, is a first-in-class anti-CEACAM1 antibody being developed to treat pancreatic and other aggressive cancers. The oncology space, worth billions, continues to see intense investor interest, especially as companies explore biomarker-driven therapies.The News: Purple Biotech unveiled final Phase 2 results showing CM24 combined with nivolumab and chemotherapy significantly improved overall survival (OS) and progression-free survival (PFS) in pancreatic cancer patients with specific biomarkers. The data revealed a 79% reduction in death risk and a 5.1-month OS improvement, particularly in biomarker-enriched patient groups.What It Means: These results not only validate CM24’s potential but also position Purple Biotech to expand its pipeline into broader cancer applications. With a planned Phase 2b trial targeting high-CEACAM1 patients, the company is tapping into precision oncology—a sector that continues to draw investor enthusiasm due to its game-changing potential.Stock Reaction: PPBT skyrocketed 151%, reflecting the market’s recognition of this major milestone in the fight against pancreatic cancer.Stocktwits.com Sentiment &amp; Popularity:<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_23_40_AM_19763a2e26.png" alt="Screenshot 2024-12-05 at 2.23.40 AM.png">&nbsp;<hr>&nbsp;<h3>2. Stereotaxis (NYSE: STXS)</h3>Background: Stereotaxis is at the forefront of surgical robotics, specializing in robotic magnetic navigation (RMN) systems for minimally invasive endovascular interventions. Its GenesisX system aims to improve precision, safety, and efficiency in procedures, a critical innovation as the global market for robotic-assisted surgeries is projected to grow at a double-digit CAGR over the next decade.The News: The GenesisX robotic system was showcased for the first time at the RSNA 2024 Annual Meeting, in collaboration with Neusoft Medical Systems. The partnership aligns GenesisX with advanced imaging technologies, offering enhanced capabilities for healthcare providers worldwide.What It Means: The exposure at RSNA, one of the largest radiology conferences globally, strengthens Stereotaxis' visibility and positions the GenesisX as a next-generation tool for minimally invasive surgeries. This partnership could unlock new revenue streams as the healthcare sector increasingly adopts robotic solutions.Stock Reaction: STXS edged up 4.18%, with investors optimistic about the long-term implications of the GenesisX system.Stocktwits.com Sentiment &amp; Popularity:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_25_09_AM_6fecf5b145.png" alt="Screenshot 2024-12-05 at 2.25.09 AM.png">&nbsp;<hr>&nbsp;<h3>3. Delcath Systems (NASDAQ: DCTH)</h3>Background: Delcath Systems focuses on innovative therapies for primary and metastatic liver cancers. Its flagship product, HEPZATO KIT™, offers a unique approach to delivering high-dose chemotherapy directly to the liver while minimizing systemic exposure. This precision is critical for targeting liver-dominant diseases—a market that represents tens of thousands of patients annually.The News: The FDA has cleared Delcath’s Phase 2 trial of HEPZATO in liver-dominant metastatic colorectal cancer. The study will compare HEPZATO plus standard chemotherapy with chemotherapy alone, aiming to validate its safety and efficacy in this high-need population.What It Means: HEPZATO has already shown promise in metastatic uveal melanoma, and this expansion could significantly broaden its market reach. The ability to address liver-dominant cancers positions Delcath as a potential leader in a niche but high-value market.Stock Reaction: DCTH rose 6.4% on the day, continuing its strong performance following a 203% year-to-date rally.&nbsp;&nbsp;<hr>&nbsp;<h3>4. BrainStorm Cell Therapeutics (NASDAQ: BCLI)</h3>Background: BrainStorm is a pioneering biotech company developing autologous adult stem cell therapies for neurodegenerative diseases like ALS and progressive MS. Its lead candidate, NurOwn®, is designed to deliver neurotrophic factors directly to damaged neurons, potentially altering the course of these debilitating diseases. With few effective therapies for ALS, the market is ripe for disruptive innovation.The News: BrainStorm announced a December 11 webinar featuring updates on its Phase 3b trial of NurOwn, aimed at refining the therapy’s efficacy for FDA approval. This comes as the company prepares for a pivotal registrational trial.What It Means: If successful, NurOwn could be the first significant breakthrough for ALS in years, addressing an unmet medical need in a multibillion-dollar market. The company’s focus on early-stage ALS patients may improve trial outcomes and strengthen its case for regulatory approval.Stock Reaction: BCLI dipped 2.66%, reflecting cautious investor sentiment as the market awaits trial data.Stocktwits.com Sentiment &amp; Popularity:<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_26_15_AM_28681ca8de.png" alt="Screenshot 2024-12-05 at 2.26.15 AM.png">&nbsp;<hr>&nbsp;<h3>5. DMG Blockchain Solutions (OTCQB: DMGGF)</h3>Background: DMG Blockchain integrates Bitcoin mining with sustainability and AI-driven data centers. Its Terra Pool initiative is designed to create a carbon-neutral Bitcoin mining ecosystem, catering to ESG-conscious investors and industries. With institutional adoption of Bitcoin accelerating, DMG’s dual focus on growth and environmental responsibility makes it a standout.The News: DMG reported November mining results of 32 BTC, an increased hashrate of 1.66 EH/s, and significant insider purchases by its CEO and COO. The company also secured $17.3 million to fund growth initiatives, including AI and blockchain infrastructure.What It Means: The raised capital and insider purchases signal confidence in DMG’s ability to scale operations and align with Bitcoin’s anticipated market growth. The focus on sustainability could attract institutional players prioritizing ESG compliance.Stock Reaction: DMGI remained stable dipping just slightly, with the market digesting the long-term growth potential from recent investments.&nbsp;<hr>&nbsp;<h3>6. BriaCell Therapeutics (NASDAQ: BCTX)</h3>Background: BriaCell specializes in novel immunotherapies targeting advanced breast cancer. Its lead therapy, Bria-IMT™, is designed to boost the immune system's response against tumors. With metastatic breast cancer affecting over 2 million women globally, there’s an urgent need for effective treatments.The News: BriaCell’s pivotal Phase 3 study of Bria-IMT received a positive safety review from the DSMB, allowing the trial to proceed without changes. The trial is being conducted under the FDA’s Fast Track Designation.What It Means: The DSMB’s approval reinforces Bria-IMT’s safety and paves the way for the company to potentially deliver a game-changing therapy for metastatic breast cancer patients. The Fast Track Designation further emphasizes its potential impact.Stock Reaction: BCTX shares soared 13%, reflecting growing investor confidence in the company’s clinical progress.Rumours from Twitter:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_27_31_AM_e685b0a306.png" alt="Screenshot 2024-12-05 at 2.27.31 AM.png">&nbsp;&nbsp;<h3>7. Laser Photonics Corporation (NASDAQ: LASE)</h3>Background: Laser Photonics Corporation specializes in industrial laser systems, providing innovative solutions for cleaning, material processing, and now pharmaceuticals. With its recent acquisition of Control Micro Systems, Inc., the company is expanding into new sectors, including the fast-growing pharmaceutical and semiconductor industries. The industrial laser market, driven by advances in automation and precision engineering, is projected to exceed $10 billion by 2030, making it a hotbed for innovation.The News: Laser Photonics announced the successful installation of a state-of-the-art pill drilling system at a customer’s facility. The system, a Class I automated CO2 laser with advanced fume extraction and machine vision inspection, is designed to streamline pill production processes. This system also doubles as an anti-counterfeiting solution, addressing critical challenges in the pharmaceutical supply chain.What It Means: This installation signifies Laser Photonics’ pivot into high-demand verticals like pharmaceuticals. By integrating advanced laser technology with automated inspection, the company is positioning itself as a key supplier in a market prioritizing efficiency, precision, and security.Stock Reaction: LASE shares declined 6.40%, reflecting broader market volatility rather than company-specific concerns. Investors appear cautiously optimistic about the company's potential in its newly targeted markets.&nbsp;Also Read:<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/featured/why-this-small-biotech-stock-could-be-primed-for-a-breakout/">&nbsp;Why This Small Biotech Stock Could Be Primed for a Breakout</a>Be the First to Know:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like&nbsp;AST SpaceMobile (NASDAQ: ASTS), which shot up&nbsp;+533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at Invest@WealthyVC.comDisclaimer: Wealthy VC does not hold a long or short position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.&nbsp;This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

News Movers: Yesterday’s Hottest News That Could Move the Needle Today

Your Only Digest of Market-Moving News and Rumours From High-Growth, Small Cap Stocks

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

BCTX
BriaCell Therapeutics Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results:

Historical Earnings

Latest BCTX News

BCTXBriaCell Therapeutics Corp